Skip to content

Nasdaq · CIK 0001600620

AUPH Aurinia Pharmaceuticals Inc.

Insider trading from SEC Form 4. Last filing 31 d ago. Close $16.65 on Oct 9, 2026, +50% from the 52-week low and -11% from the high.

Last 90 days

Net insider value
-$190k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$190k by 1 insider
Insiders on file
13
with a Form 4 at this company

Price and insider trades, last year

AUPHOct 9, 2026 · close 16.65

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Aurinia Pharmaceuticals Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
27WeakStephen P. Robertson
Chief Legal Officer
sell
$190k
11,939 shares
-2%-
43ModerateKevin Tang
director
buy
$14M
1,300,000 shares
+13%+61% from low0% from high
32WeakGreg Keenan
Chief Medical Officer
sell
$210k
20,000 shares
-13%+61% from low0% from high
38WeakGreg Keenan
Chief Medical Officer
sell
$68k
8,305 shares
-5%-
48ModerateKevin Tang
director
buy
$13M
1,600,000 shares
+19%-
65NotableMatthew Maxwell Donley
Chief Operating Officer
sell
$994k
124,893 shares
-16%-
60NotableStephen P. Robertson
EVP, General Counsel
sell
$975k
122,479 shares
-19%-
66NotableJoseph M Miller
Chief Financial Officer
sell
$940k
118,013 shares
-17%-
40ModerateGreg Keenan
Chief Medical Officer
sell
$98k
12,239 shares
-7%-
70NotablePeter Greenleaf
Chief Executive Officer
sell
$2.9M
360,540 shares
-17%-
43ModerateKevin Tang
director
buy
$11M
1,200,000 shares
+17%-
24WeakKaren L. Smith
director
sell
$44k
5,241 shares
-29%-
24WeakJeffrey Allen Bailey
director
sell
$38k
4,557 shares
-25%-

Transactions

The last 58 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 10, 2026Stephen P. Robertson
Chief Legal Officer
SOpen-market sale
Common Stock
-11,939$15.95$190k588,84831 d ago
Aug 1, 2025Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+1,000,000$10.12$10M11,029,500Aug 5, 2025
Aug 1, 2025Greg Keenan
Chief Medical Officer
SOpen-market sale
Common Stock
-20,000$10.50$210k133,484Aug 5, 2025
Aug 4, 2025Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+100,000$11.34$1.1M11,129,500Aug 5, 2025
Aug 5, 2025Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+200,000$11.68$2.3M11,329,500Aug 5, 2025
May 16, 2025Jeffrey Allen Bailey
director
AGrant or award
Director Stock Option (right to buy)derivative
+37,485$0.00$037,485May 16, 2025
May 16, 2025Kathleen Goetz
director
AGrant or award
Director Stock Option (right to buy)derivative
+63,724$0.00$063,724May 16, 2025
May 16, 2025Craig A Johnson
director
AGrant or award
Director Stock Option (right to buy)derivative
+37,485$0.00$037,485May 16, 2025
May 16, 2025Tina Susan Nova
director
AGrant or award
Director Stock Option (right to buy)derivative
+63,724$0.00$063,724May 16, 2025
Mar 7, 2025Greg Keenan
Chief Medical Officer
SOpen-market sale
Common Stock
-8,305$8.23$68k153,484Mar 7, 2025
Feb 28, 2025Matthew Maxwell Donley
Chief Operating Officer
AGrant or award
Common Stock
+82,781$0.00$0669,791Mar 4, 2025
Feb 28, 2025Peter Greenleaf
Chief Executive Officer
AGrant or award
Common Stock
+290,728$0.00$01,815,780Mar 4, 2025
Feb 28, 2025Greg Keenan
Chief Medical Officer
AGrant or award
Common Stock
+62,583$0.00$0174,028Mar 4, 2025
Feb 28, 2025Joseph M Miller
Chief Financial Officer
AGrant or award
Common Stock
+81,457$0.00$0580,663Mar 4, 2025
Feb 28, 2025Stephen P. Robertson
EVP, General Counsel
AGrant or award
Common Stock
+84,106$0.00$0529,349Mar 4, 2025
Feb 28, 2025Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+399,280$7.85$3.1M8,828,780Mar 4, 2025
Mar 3, 2025Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+100,720$7.97$803k8,929,500Mar 4, 2025
Mar 3, 2025Matthew Maxwell Donley
Chief Operating Officer
AGrant or award
Common Stock
+135,567$0.00$0805,358Mar 4, 2025
Mar 3, 2025Stephen P. Robertson
EVP, General Counsel
AGrant or award
Common Stock
+102,406$0.00$0631,755Mar 4, 2025
Mar 3, 2025Joseph M Miller
Chief Financial Officer
AGrant or award
Common Stock
+114,711$0.00$0695,374Mar 4, 2025
Mar 3, 2025Greg Keenan
Chief Medical Officer
SOpen-market sale
Common Stock
-12,239$8.00$98k161,789Mar 4, 2025
Mar 3, 2025Peter Greenleaf
Chief Executive Officer
AGrant or award
Common Stock
+333,705$0.00$02,149,485Mar 4, 2025
Mar 3, 2025Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+351,962$8.02$2.8M9,281,462Mar 4, 2025
Mar 3, 2025Matthew Maxwell Donley
Chief Operating Officer
SOpen-market sale
Common Stock
-65,902$8.00$527k739,456Mar 4, 2025
Mar 3, 2025Stephen P. Robertson
EVP, General Counsel
SOpen-market sale
Common Stock
-64,872$8.00$519k566,883Mar 4, 2025
Mar 3, 2025Joseph M Miller
Chief Financial Officer
SOpen-market sale
Common Stock
-61,859$8.00$495k633,515Mar 4, 2025
Mar 3, 2025Peter Greenleaf
Chief Executive Officer
SOpen-market sale
Common Stock
-195,593$8.00$1.6M1,953,892Mar 4, 2025
Feb 28, 2025Greg Keenan
Chief Medical Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+95,570$0.00$095,570Mar 4, 2025
Mar 4, 2025Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+148,038$8.00$1.2M9,429,500Mar 4, 2025
Mar 4, 2025Peter Greenleaf
Chief Executive Officer
SOpen-market sale
Common Stock
-164,947$7.92$1.3M1,788,945Mar 4, 2025
Mar 4, 2025Matthew Maxwell Donley
Chief Operating Officer
SOpen-market sale
Common Stock
-58,991$7.92$467k680,465Mar 4, 2025
Mar 4, 2025Stephen P. Robertson
EVP, General Counsel
SOpen-market sale
Common Stock
-57,607$7.92$456k509,276Mar 4, 2025
Mar 4, 2025Joseph M Miller
Chief Financial Officer
SOpen-market sale
Common Stock
-56,154$7.92$445k577,361Mar 4, 2025
Feb 28, 2025Stephen P. Robertson
EVP, General Counsel
AGrant or award
Employee Stock Option (right to buy)derivative
+128,438$0.00$0128,438Mar 4, 2025
Feb 28, 2025Joseph M Miller
Chief Financial Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+124,393$0.00$0124,393Mar 4, 2025
Mar 4, 2025Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+500,000$7.92$4.0M9,929,500Mar 4, 2025
Feb 28, 2025Peter Greenleaf
Chief Executive Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+443,973$0.00$0443,973Mar 4, 2025
Feb 28, 2025Matthew Maxwell Donley
Chief Operating Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+126,416$0.00$0126,416Mar 4, 2025
Mar 4, 2025Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+100,000$8.09$809k10,029,500Mar 4, 2025
Dec 5, 2024Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+300,000$8.91$2.7M7,529,500Dec 9, 2024
Dec 6, 2024Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+400,000$9.01$3.6M7,929,500Dec 9, 2024
Dec 9, 2024Kevin Tang
director
POpen-market purchase
Common Sharesindirect: By LP
+500,000$9.09$4.5M8,429,500Dec 9, 2024
Nov 21, 2024Jeffrey Allen Bailey
director
AGrant or award
Common Shares
+12,135$0.00$025,491Nov 25, 2024
Nov 21, 2024Karen L. Smith
director
AGrant or award
Common Shares
+12,135$0.00$024,807Nov 25, 2024
Nov 21, 2024Jill Leversage
director
AGrant or award
Common Shares
+12,135$0.00$025,053Nov 25, 2024
Nov 21, 2024Craig A Johnson
director
AGrant or award
Common Shares
+20,631$0.00$020,631Nov 25, 2024
Nov 21, 2024David R.W. Jayne
director
AGrant or award
Common Shares
+12,135$0.00$056,499Nov 25, 2024
Nov 21, 2024Jeffrey Allen Bailey
director
AGrant or award
Director Stock Option (right to buy)derivative
+18,641$0.00$018,641Nov 25, 2024
Nov 21, 2024Craig A Johnson
director
AGrant or award
Director Stock Option (right to buy)derivative
+31,688$0.00$031,688Nov 25, 2024
Nov 21, 2024David R.W. Jayne
director
AGrant or award
Director Stock Option (right to buy)derivative
+18,641$0.00$018,641Nov 25, 2024
Nov 21, 2024Jill Leversage
director
AGrant or award
Director Stock Option (right to buy)derivative
+18,641$0.00$018,641Nov 25, 2024
Nov 21, 2024Karen L. Smith
director
AGrant or award
Director Stock Option (right to buy)derivative
+18,641$0.00$018,641Nov 25, 2024
Nov 8, 2024Karen L. Smith
director
MOption exercise
Common Stock
+17,913--17,913Nov 12, 2024
Nov 8, 2024Jeffrey Allen Bailey
director
MOption exercise
Common Stock
+17,913--17,913Nov 12, 2024
Nov 11, 2024Karen L. Smith
director
SOpen-market sale
Common Stock
-5,241$8.43$44k12,672Nov 12, 2024
Nov 11, 2024Jeffrey Allen Bailey
director
SOpen-market sale
Common Stock
-4,557$8.43$38k13,356Nov 12, 2024
Nov 8, 2024Karen L. Smith
director
MOption exercise
Restricted Stock Unitsderivative
-17,913$0.00$00Nov 12, 2024
Nov 8, 2024Jeffrey Allen Bailey
director
MOption exercise
Restricted Stock Unitsderivative
-17,913$0.00$00Nov 12, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

AUPH insider trading: Aurinia Pharmaceuticals Inc. | InsiderTell